WO1998045427A3 - Insulin-like growth factor agonist peptides - Google Patents

Insulin-like growth factor agonist peptides Download PDF

Info

Publication number
WO1998045427A3
WO1998045427A3 PCT/US1998/006514 US9806514W WO9845427A3 WO 1998045427 A3 WO1998045427 A3 WO 1998045427A3 US 9806514 W US9806514 W US 9806514W WO 9845427 A3 WO9845427 A3 WO 9845427A3
Authority
WO
WIPO (PCT)
Prior art keywords
insulin
growth factor
factor agonist
agonist peptides
igf
Prior art date
Application number
PCT/US1998/006514
Other languages
French (fr)
Other versions
WO1998045427A2 (en
Inventor
Ross G Clark
Henry B Lowman
Iain C A F Robinson
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Priority to EP98915236A priority Critical patent/EP0972020B1/en
Priority to JP54289498A priority patent/JP4562814B2/en
Priority to AU69470/98A priority patent/AU732989B2/en
Priority to CA002286264A priority patent/CA2286264A1/en
Priority to AT98915236T priority patent/ATE224951T1/en
Priority to DE69808258T priority patent/DE69808258T2/en
Priority to IL13192598A priority patent/IL131925A0/en
Priority to DK98915236T priority patent/DK0972020T3/en
Publication of WO1998045427A2 publication Critical patent/WO1998045427A2/en
Publication of WO1998045427A3 publication Critical patent/WO1998045427A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors (Somatomedins), e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4743—Insulin-like growth factor binding protein
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/12—Growth hormone, growth factor other than t-cell or b-cell growth factor, and growth hormone releasing factor; related peptides

Abstract

The present invention relates to the use of insulin-like growth factor agonist molecules for the preparation of a pharmaceutical composition for the stimulation of cartilage growth. These compositions inhibit the interaction of an IGF with any (one) of its binding proteins but do not bind to a human IGF receptor.
PCT/US1998/006514 1997-04-04 1998-03-31 Insulin-like growth factor agonist peptides WO1998045427A2 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
EP98915236A EP0972020B1 (en) 1997-04-04 1998-03-31 Insulin-like growth factor agonist molecules
JP54289498A JP4562814B2 (en) 1997-04-04 1998-03-31 Insulin-like growth factor agonist molecule
AU69470/98A AU732989B2 (en) 1997-04-04 1998-03-31 Insulin-like growth factor agonist molecules
CA002286264A CA2286264A1 (en) 1997-04-04 1998-03-31 Insulin-like growth factor agonist peptides
AT98915236T ATE224951T1 (en) 1997-04-04 1998-03-31 INSULIN-LIKE GROWTH FACTOR MOLECULE AGONISTS
DE69808258T DE69808258T2 (en) 1997-04-04 1998-03-31 MOLECULE AGONISTS FOR THE INSULIN-LIKE GROWTH FACTOR
IL13192598A IL131925A0 (en) 1997-04-04 1998-03-31 Insulin-like growth factor agonist molecules
DK98915236T DK0972020T3 (en) 1997-04-04 1998-03-31 Agonist molecules directed against insulin-like growth factors

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/825,852 1997-04-04
US08/825,852 US6121416A (en) 1997-04-04 1997-04-04 Insulin-like growth factor agonist molecules

Publications (2)

Publication Number Publication Date
WO1998045427A2 WO1998045427A2 (en) 1998-10-15
WO1998045427A3 true WO1998045427A3 (en) 1999-01-07

Family

ID=25245064

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1998/006514 WO1998045427A2 (en) 1997-04-04 1998-03-31 Insulin-like growth factor agonist peptides

Country Status (13)

Country Link
US (16) US6121416A (en)
EP (2) EP1251137A3 (en)
JP (1) JP4562814B2 (en)
AT (1) ATE224951T1 (en)
AU (1) AU732989B2 (en)
CA (1) CA2286264A1 (en)
DE (1) DE69808258T2 (en)
DK (1) DK0972020T3 (en)
ES (1) ES2183344T3 (en)
HK (1) HK1047755A1 (en)
IL (1) IL131925A0 (en)
PT (1) PT972020E (en)
WO (1) WO1998045427A2 (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8954128B2 (en) 2008-03-28 2015-02-10 Dexcom, Inc. Polymer membranes for continuous analyte sensors
US9020572B2 (en) 2008-02-21 2015-04-28 Dexcom, Inc. Systems and methods for processing, transmitting and displaying sensor data
US9173607B2 (en) 2008-03-28 2015-11-03 Dexcom, Inc. Polymer membranes for continuous analyte sensors
US9414777B2 (en) 2004-07-13 2016-08-16 Dexcom, Inc. Transcutaneous analyte sensor

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6420518B1 (en) 1997-04-04 2002-07-16 Genetech, Inc. Insulin-like growth factor agonist molecules
ES2329220T3 (en) 1999-01-06 2009-11-24 Genentech, Inc. MUTANT VARIANTS OF THE INSULIN SIMILAR GROWTH FACTOR (IGF)
EP1141014B1 (en) 1999-01-06 2004-12-08 Genentech, Inc. Insulin-like growth factor (igf) i mutant variant
US20030224017A1 (en) * 2002-03-06 2003-12-04 Samal Siba K. Recombinant Newcastle disease viruses useful as vaccines or vaccine vectors
ATE321885T1 (en) * 1999-10-29 2006-04-15 Univ Oregon Health Sciences MODULATION OF NEUROCRINE DIFFERENTIATION BY PROTEIN 25.1
WO2001072323A2 (en) 2000-03-24 2001-10-04 Genentech, Inc. Use of insulin for the treatment of cartilagenous disorders
EP1282437B1 (en) 2000-05-16 2008-03-19 Genentech, Inc. Treatment of cartilage disorders
FR2810675B1 (en) * 2000-06-22 2002-09-27 Pf Medicament MODIFIED CONSTRUCTION DOWNSTREAM OF THE INITIATION CODON FOR OVEREXPRESSION OF RECOMBINANT PROTEINS
CA2429615C (en) * 2000-11-28 2016-07-12 Children's Medical Center Corporation Determination of risk and treatment of complications of prematurity
US7611711B2 (en) * 2001-01-17 2009-11-03 Vegenics Limited VEGFR-3 inhibitor materials and methods
AU2002255508B2 (en) 2001-02-09 2008-04-03 Genentech, Inc. Crystallization of IGF-1
US6555581B1 (en) 2001-02-15 2003-04-29 Jones Pharma, Inc. Levothyroxine compositions and methods
US6790672B2 (en) * 2001-02-19 2004-09-14 Board Of Regents The University Of Texas System Encoded molecular sieve particle-based sensors
JP4117731B2 (en) 2001-03-14 2008-07-16 ジェネンテック・インコーポレーテッド IGF antagonist peptide
US6841386B2 (en) 2001-04-10 2005-01-11 Viacell, Inc. Modulation of primary stem cell differentiation using an insulin-like growth factor binding protein
AU2002363800A1 (en) * 2001-11-13 2003-05-26 Loi Tran Therapeutic agent composition and method of use
US20100247483A1 (en) * 2001-11-13 2010-09-30 Tran Loi H Therapeutic agent composition and method of use
US7232798B2 (en) 2001-11-13 2007-06-19 Tran Loi H Neuroprotection and neuroegenisis by administering cyclic prolyl glycine
WO2003100008A2 (en) 2002-05-24 2003-12-04 Schering Corporation Neutralizing human anti-igfr antibody
EP1535065A4 (en) * 2002-06-11 2007-07-11 Burnham Inst Neuroprotective synergy of erythropoietin and insulin-like growth factor
US7118877B2 (en) * 2002-07-08 2006-10-10 Wyeth Caspase 9 activation and uses therefor
JP4719465B2 (en) * 2002-09-04 2011-07-06 ディーエスエム アイピー アセッツ ビー．ブイ． A nutritional and therapeutic composition comprising an insulin sensitivity enhancer and a peptide fraction
US20040121407A1 (en) * 2002-09-06 2004-06-24 Elixir Pharmaceuticals, Inc. Regulation of the growth hormone/IGF-1 axis
US7279971B2 (en) * 2002-09-06 2007-10-09 Telefonaktiebolaget Lm Ericsson (Publ) Composite power amplifier
NZ539218A (en) * 2002-09-18 2008-03-28 Univ Montreal Ct Hospitalier Chum Synthetic GHRH analogues of 29 amino acids or more
WO2004043395A2 (en) * 2002-11-14 2004-05-27 Wyeth Methods and compositions for treating neurological disorders
US7273788B2 (en) * 2003-05-21 2007-09-25 Micron Technology, Inc. Ultra-thin semiconductors bonded on glass substrates
EP2367008A3 (en) 2003-06-06 2014-12-24 Genentech, Inc. Modulating the interaction between HGF beta chain and C-Met
US7920906B2 (en) 2005-03-10 2011-04-05 Dexcom, Inc. System and methods for processing analyte sensor data for sensor calibration
NZ545940A (en) 2003-09-12 2009-12-24 Tercica Inc Methods for treatment of insulin-like growth factor-1 (IGF-1) deficiency
US7192738B2 (en) * 2003-10-03 2007-03-20 Genentech, Inc. IGF binding proteins
EP1694850B1 (en) 2003-11-12 2011-06-29 Schering Corporation Plasmid system for multigene expression
US9247900B2 (en) 2004-07-13 2016-02-02 Dexcom, Inc. Analyte sensor
TW200526684A (en) 2003-11-21 2005-08-16 Schering Corp Anti-IGFR1 antibody therapeutic combinations
CA2548282A1 (en) 2003-12-11 2005-06-30 Genentech, Inc. Methods and compositions for inhibiting c-met dimerization and activation
WO2005090579A1 (en) * 2004-03-19 2005-09-29 Merck Patent Gmbh Modified bouganin proteins, cytotoxins and methods and uses thereof
WO2006127694A2 (en) 2004-07-13 2006-11-30 Dexcom, Inc. Analyte sensor
WO2006060419A2 (en) 2004-12-03 2006-06-08 Schering Corporation Biomarkers for pre-selection of patients for anti-igf1r therapy
US7833513B2 (en) 2004-12-03 2010-11-16 Rhode Island Hospital Treatment of Alzheimer's Disease
CA2604393A1 (en) * 2005-04-15 2006-10-26 Schering Corporation Methods and compositions for treating or preventing cancer
WO2006138315A2 (en) * 2005-06-15 2006-12-28 Schering Corporation Anti-igf1r antibody formulations
CA2648322C (en) 2006-04-10 2017-11-28 Genentech, Inc. Disheveled pdz modulators
EP2148695B1 (en) 2007-04-18 2014-10-15 Premacure AB Method and product for treatment and/or prevention of complications of prematurity
CA2697057A1 (en) 2007-08-22 2009-02-26 Gilead Colorado, Inc. Therapy for complications of diabetes
US11730407B2 (en) 2008-03-28 2023-08-22 Dexcom, Inc. Polymer membranes for continuous analyte sensors
US9238080B2 (en) 2010-05-21 2016-01-19 Merrimack Pharmaceuticals, Inc. Bi-specific fusion proteins
WO2012054565A1 (en) 2010-10-20 2012-04-26 Genentech, Inc. Methods and compositions for modulating the wnt pathway
MX2014004027A (en) 2011-10-14 2014-04-30 Genentech Inc Zymogen activators.
JP6134725B2 (en) 2011-10-14 2017-05-24 ジェネンテック， インコーポレイテッド BACE1 peptide inhibitors
EP3355907B1 (en) 2015-10-02 2021-01-20 Silver Creek Pharmaceuticals, Inc. Bi-specific therapeutic proteins for tissue repair
EP3681602A1 (en) 2017-09-11 2020-07-22 Shire Human Genetic Therapies, Inc. Methods and compositions for treating chronic lung diseases
AU2019271189A1 (en) 2018-05-15 2021-01-07 Lloyd Hung Loi TRAN Therapeutic agent composition and method of use, for treatment of mild cognitive impairment, depression, and psychological disorders
WO2021005604A1 (en) 2019-07-11 2021-01-14 Opko Biologics Ltd. Long-acting igf-1 or igf-1 variants and methods of producing same
GB201913196D0 (en) 2019-09-12 2019-10-30 Univ Newcastle Culture method
TW202233228A (en) 2020-10-19 2022-09-01 美商舒爾人類基因療法公司 Compositions suitable for use in neonates
DE102021122096A1 (en) 2021-08-26 2023-03-02 Forschungsinstitut für Nutztierbiologie Compositions comprising IGF-1, IGFBP-2 and insulin and their use
WO2023139115A1 (en) 2022-01-19 2023-07-27 Oak Hill Bio Limited Compositions and methods for reducing oxidation of igf‐1/igfbp
CN117347626B (en) * 2023-12-06 2024-03-12 安徽惠邦生物工程有限公司 Human insulin-like growth factor binding protein-1 chemiluminescence immunoassay kit and preparation method thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992015679A1 (en) * 1991-03-01 1992-09-17 Protein Engineering Corporation Improved epitode displaying phage
WO1994004569A1 (en) * 1992-08-20 1994-03-03 The Agricultural And Food Research Council Use of specific binding molecules in potentiating igf-i activity
WO1995007697A2 (en) * 1993-09-15 1995-03-23 Warner-Lambert Company Use of thiazolidinedione derivatives and related antihyperglycemic agents in the treatment of disease states at risk for progressing to noninsulin-dependent diabetes mellitus
EP0681842A2 (en) * 1990-11-19 1995-11-15 Genentech, Inc. Ligand-mediated immunofunctional hormone binding protein assay method

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4411890A (en) * 1981-04-14 1983-10-25 Beckman Instruments, Inc. Synthetic peptides having pituitary growth hormone releasing activity
US3721252A (en) * 1971-04-01 1973-03-20 Catheter And Instr Corp Spring guide washer
US4511503A (en) * 1982-12-22 1985-04-16 Genentech, Inc. Purification and activity assurance of precipitated heterologous proteins
IL71991A (en) * 1983-06-06 1994-05-30 Genentech Inc Preparation of mature human IGF and EGF via prokaryotic recombinant DNA technology
PH23185A (en) 1983-06-13 1989-05-29 Scheindel Ass Inc Pressure operated dispensing container
WO1985000831A1 (en) * 1983-08-10 1985-02-28 Amgen Microbial expression of insulin-like growth factor
EP0134094B1 (en) 1983-08-15 1987-05-27 AMP INCORPORATED (a New Jersey corporation) An improved compliant section for circuit board contact elements
AU598205B2 (en) * 1985-08-22 1990-06-21 Gropep Pty Ltd Peptide analogues of mammalian insulin-like growth factor-1
SE8505922D0 (en) * 1985-12-13 1985-12-13 Kabigen Ab CONSTRUCTION OF AN IGG BINDING PROTEIN TO FACILITATE DOWNSTREAM PROCESSING USING PROTEIN ENGINEERING
WO1988007863A1 (en) * 1987-04-06 1988-10-20 Biogrowth, Inc. Human somatomedin carrier protein subunits and process for producing them
ATE109828T1 (en) * 1987-04-23 1994-08-15 Monsanto Co SECRETION OF AN INSULIN-LIKE GROWTH FACTOR IN E. COLI.
SE8703625D0 (en) * 1987-09-18 1987-09-18 Kabivitrum Ab NEW MEDICAL USE
US4876242A (en) * 1987-09-21 1989-10-24 Merck & Co., Inc. Human insulin-like growth factor analoges with reduced binding to serum carrier proteins and their production in yeast
US5470828A (en) * 1987-12-24 1995-11-28 Gropep Pty. Ltd. Peptide analogs of insulin-like growth factor II
JP2507106B2 (en) * 1987-12-24 1996-06-12 グロペップ プロプライエタリー リミテッド Insulin-like growth factor 1 (IGF-1) or factor 2 (IGF-2) related peptides
US4988675A (en) * 1988-02-05 1991-01-29 Ciba-Geigy Corporation Method for preventing secondary effects
DE68905203T2 (en) * 1988-02-05 1993-07-22 Ciba Geigy Ag USE OF IGF I FOR PRODUCING A PREPARATION FOR THE TREATMENT OF KIDNEY DISEASES.
DK131988A (en) * 1988-03-11 1989-09-12 Erasmus University IGF BINDING PROTEIN, DNA STRUCTURE CODING FOR IGF BINDING PROTEIN AND VECTOR CONTAINING THIS DNA STRUCTURE
US5258287A (en) * 1988-03-22 1993-11-02 Genentech, Inc. DNA encoding and methods of production of insulin-like growth factor binding protein BP53
ATE132164T1 (en) * 1988-04-12 1996-01-15 Amgen Boulder Inc METHOD FOR INCREASE AND INHIBITING THE EFFECT OF AN INSULIN-LIKE GROWTH FACTOR
US5223409A (en) * 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5534617A (en) * 1988-10-28 1996-07-09 Genentech, Inc. Human growth hormone variants having greater affinity for human growth hormone receptor at site 1
GB8826451D0 (en) * 1988-11-11 1988-12-14 Sandoz Ltd Improvements in/relating to organic compounds
IL92816A0 (en) * 1988-12-22 1990-09-17 Biogrowth Inc Recombinant dna molecules,hosts,processes and human somatomedin carrier protein-like polypeptides
CA2007886A1 (en) * 1989-01-17 1990-07-17 Marvin L. Bayne Human insulin-like growth factor analogs with reduced binding to 28 k igf binding proteins and their production in yeast
US5093317A (en) * 1989-06-05 1992-03-03 Cephalon, Inc. Treating disorders by application of insulin-like growth factor
US5652214A (en) * 1989-06-05 1997-07-29 Cephalon, Inc. Treating disorders by application of insulin-like growth factors and analogs
GB8920381D0 (en) * 1989-09-08 1989-10-25 Greater Glasgow Health Board Treatment of insulin-resistant diabetes
US5374620A (en) * 1990-06-07 1994-12-20 Genentech, Inc. Growth-promoting composition and its use
US5126324A (en) * 1990-06-07 1992-06-30 Genentech, Inc. Method of enhancing growth in patients using combination therapy
US5593844A (en) * 1990-11-19 1997-01-14 Genentech, Inc. Ligand-mediated immunofunctional hormone binding protein assay method
SE9100099D0 (en) * 1991-01-11 1991-01-11 Kabi Pharmacia Ab USE OF GROWTH FACTOR
US5187151A (en) * 1991-02-12 1993-02-16 Genentech, Inc. Use of binding protein with igf-i as an anabolic growth promoting agent
US5206235A (en) * 1991-03-20 1993-04-27 Merck & Co., Inc. Benzo-fused lactams that promote the release of growth hormone
US5202119A (en) * 1991-06-28 1993-04-13 Genentech, Inc. Method of stimulating immune response
EP0597033B1 (en) * 1991-08-01 1997-04-09 Genentech, Inc. Igf-1 to improve the neural condition
US6310040B1 (en) * 1991-11-08 2001-10-30 Cephalon, Inc. Treating retinal neuronal disorders by the application of insulin-like growth factors and analogs
SE9201573D0 (en) * 1992-05-19 1992-05-19 Kabi Pharmacia Ab USE OF IGF-1
CA2136969C (en) * 1992-06-12 2009-03-24 Michael E. Lewis Prevention and treatment of peripheral neuropathy
US5273961A (en) * 1992-09-22 1993-12-28 Genentech, Inc. Method of prophylaxis of acute renal failure
CA2132871A1 (en) * 1993-01-25 1994-08-04 Alan C. Moses Method for modifying, diagnosing, and screening for igf-i sensitive cell barrier properties
WO1994016723A2 (en) * 1993-01-29 1994-08-04 Synergen, Inc. Wound healing composition
CA2179598A1 (en) * 1993-12-23 1995-06-29 Nils Langeland Johansen Compounds with growth hormone releasing properties
SK281963B6 (en) * 1993-12-23 2001-09-11 Novo Nordisk A/S Compounds with growth hormone releasing properties, pharmaceutical compositions comprising them and their use
SE9402370D0 (en) * 1994-07-04 1994-07-04 Pharmacia Ab Use of IGF-I
US5798337A (en) * 1994-11-16 1998-08-25 Genentech, Inc. Low molecular weight peptidomimetic growth hormone secretagogues
SE9501472D0 (en) * 1995-04-21 1995-04-21 Pharmacia Ab Truncated IGF-I
US5622932A (en) * 1995-05-05 1997-04-22 Eli Lilly And Company IGF-1 superagonists
EP0828758B1 (en) * 1995-05-26 2001-08-29 Theratechnologies Inc. Chimeric fatty body-pro-grf analogs with increased biological potency
CA2223833C (en) * 1995-06-07 2010-12-21 Nicholas C. Wrighton Compounds and peptides that bind to the erythropoietin receptor
DK0885242T3 (en) * 1995-06-07 2008-07-14 Glaxo Group Ltd Peptides and compounds that bind to a thrombopoietin receptor
YU34196A (en) * 1995-06-07 1999-03-04 Glaxo Group Limited Peptides and compounds that bind to a receptor
US5958872A (en) * 1996-04-01 1999-09-28 Apoptosis Technology, Inc. Active survival domains of IGF-IR and methods of use
EP0854884A1 (en) * 1996-04-17 1998-07-29 Neurocrine Biosciences, Inc. Ligand inhibitors of insulin-like growth factor binding proteins and methods of use therefor
WO1997040750A1 (en) 1996-04-25 1997-11-06 Karl Storz Gmbh & Co. Surgical instrument system
US6428781B1 (en) 1996-12-27 2002-08-06 Daiichi Pharmaceutical Co., Ltd. Composition of an endogenous insulin-like growth factor-II derivative
US6420518B1 (en) * 1997-04-04 2002-07-16 Genetech, Inc. Insulin-like growth factor agonist molecules
AU6515499A (en) 1998-10-16 2000-05-08 Musc Foundation For Research Development Fragments of insulin-like growth factor binding protein and insulin-like growth factor, and uses thereof

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0681842A2 (en) * 1990-11-19 1995-11-15 Genentech, Inc. Ligand-mediated immunofunctional hormone binding protein assay method
WO1992015679A1 (en) * 1991-03-01 1992-09-17 Protein Engineering Corporation Improved epitode displaying phage
WO1994004569A1 (en) * 1992-08-20 1994-03-03 The Agricultural And Food Research Council Use of specific binding molecules in potentiating igf-i activity
WO1995007697A2 (en) * 1993-09-15 1995-03-23 Warner-Lambert Company Use of thiazolidinedione derivatives and related antihyperglycemic agents in the treatment of disease states at risk for progressing to noninsulin-dependent diabetes mellitus

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
BAR R. S. ET AL.: "Tissue localization of perfused endothelial cell IGF binding protein is markedly altered by association with IGF-1.", ENDOCRINOLOGY, vol. 127, no. 4, 1990, pages 3243 - 3245, XP002074892 *
BAYNE M. L. ET AL.: "THE ROLES OF TYROSINES 24, 31, AND 60 IN THE HIGH AFFINITY BINDING OF INSULIN-LIKE GROWTH FACTOR-I TO THE TYPE 1 INSULIN-LIKE GROWTH FACTOR RECEPTOR", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 265, no. 26, 15 September 1990 (1990-09-15), pages 15648 - 15652, XP002039492 *
CASCIERI M. A. ET AL.: "MUTANTS OF HUMAN INSULIN-LIKE GROWTH FACTOR I WITH REDUCED AFFINITY FOR THE TYPE 1 INSULIN-LIKE GROWTH FACTOR RECEPTOR", BIOCHEMISTRY, vol. 27, no. 9, 3 May 1988 (1988-05-03), pages 3229 - 3233, XP002039493 *
DEVLIN J. J. ET AL.: "RANDOM PEPTIDE LIBRARIES: A SOURCE OF SPECIFIC PROTEIN BINDING MOLECULES", SCIENCE, vol. 249, 27 July 1990 (1990-07-27), pages 404 - 406, XP000616029 *
KAY B. K. ET AL.: "An M13 phage library displaying random 38-amino-acid peptides as a source of novel sequences with affinity to selected targets.", GENE, vol. 128, 1993, pages 59 - 65, XP002074893 *
KLETZIEN R. F. ET AL.: "Enhancement of adipocyte differentiation by an insulin-sensitizing agent.", MOLECULAR PHARMACOLOGY, vol. 41, no. 2, 1992, pages 393 - 398, XP002081233 *
LODDICK S. A . ET AL.: "Displacement of insulin-like growth factors from their binding proteins a s a potential treatment for stroke.", PROC. NATL. ACAD. SCI. USA, vol. 95, February 1998 (1998-02-01), pages 1894 - 1898, XP002074895 *
LOWMAN H. B. ET AL.: "Molecular mimics of insulin-like growth factor 1 (IGF-1) for inhibiting IGF-1: IGF-binding protein interactions.", BIOCHEMISTRY, vol. 37, 23 June 1998 (1998-06-23), pages 8870 - 8878, XP002074896 *
SCOTT J. K. ET AL.: "SEARCHING FOR PEPTIDE LIGANDS WITH AN EPITOPE LIBRARY", SCIENCE, vol. 249, 27 July 1990 (1990-07-27), pages 386 - 390, XP000571645 *
WRIGHTON N. C. ET AL.: "Small peptides as potent mimetics of the protein hormone erythropoietin.", SCIENCE, vol. 273, July 1996 (1996-07-01), pages 458 - 463, XP002074894 *

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9414777B2 (en) 2004-07-13 2016-08-16 Dexcom, Inc. Transcutaneous analyte sensor
US9020572B2 (en) 2008-02-21 2015-04-28 Dexcom, Inc. Systems and methods for processing, transmitting and displaying sensor data
US9143569B2 (en) 2008-02-21 2015-09-22 Dexcom, Inc. Systems and methods for processing, transmitting and displaying sensor data
US8954128B2 (en) 2008-03-28 2015-02-10 Dexcom, Inc. Polymer membranes for continuous analyte sensors
US9173607B2 (en) 2008-03-28 2015-11-03 Dexcom, Inc. Polymer membranes for continuous analyte sensors
US9173606B2 (en) 2008-03-28 2015-11-03 Dexcom, Inc. Polymer membranes for continuous analyte sensors
US9549699B2 (en) 2008-03-28 2017-01-24 Dexcom, Inc. Polymer membranes for continuous analyte sensors
US9566026B2 (en) 2008-03-28 2017-02-14 Dexcom, Inc. Polymer membranes for continuous analyte sensors
US9572523B2 (en) 2008-03-28 2017-02-21 Dexcom, Inc. Polymer membranes for continuous analyte sensors

Also Published As

Publication number Publication date
ES2183344T3 (en) 2003-03-16
US6693079B1 (en) 2004-02-17
US6121416A (en) 2000-09-19
EP1251137A2 (en) 2002-10-23
CA2286264A1 (en) 1998-10-15
US6689751B1 (en) 2004-02-10
US6949349B1 (en) 2005-09-27
HK1047755A1 (en) 2003-03-07
DE69808258D1 (en) 2002-10-31
AU732989B2 (en) 2001-05-03
US6635619B1 (en) 2003-10-21
AU6947098A (en) 1998-10-30
DE69808258T2 (en) 2003-09-18
US6632794B1 (en) 2003-10-14
US6677305B1 (en) 2004-01-13
DK0972020T3 (en) 2003-02-03
US6713451B1 (en) 2004-03-30
WO1998045427A2 (en) 1998-10-15
EP0972020A1 (en) 2000-01-19
PT972020E (en) 2003-02-28
EP0972020B1 (en) 2002-09-25
US6680298B1 (en) 2004-01-20
JP2002510194A (en) 2002-04-02
US6716586B1 (en) 2004-04-06
JP4562814B2 (en) 2010-10-13
US6683053B1 (en) 2004-01-27
IL131925A0 (en) 2001-03-19
ATE224951T1 (en) 2002-10-15
US6251865B1 (en) 2001-06-26
US6645775B1 (en) 2003-11-11
US6620789B1 (en) 2003-09-16
EP1251137A3 (en) 2003-04-16
US6608031B1 (en) 2003-08-19
US6693078B1 (en) 2004-02-17

Similar Documents

Publication Publication Date Title
WO1998045427A3 (en) Insulin-like growth factor agonist peptides
HUP9701554D0 (en) Pharmaceutical composition containing plazma proteins
IL95118A0 (en) Polypeptide derivatives,their preparation and pharmaceutical compositions containing them
ATE425181T1 (en) THERAPEUTIC COMPOSITIONS OF ANTIBODIES AND ANTISENS NUCLEIC ACIDS AGAINST SERRATE
EP1717315A3 (en) Osteoprotegerin binding proteins and receptors
BG102817A (en) Modulators of factor traf asociated with tnf-receptor, their preparation and application
WO2000002916A3 (en) PEPTIDE COMPOSITIONS MIMICKING TGF-β ACTIVITY
WO1997046585A3 (en) Fragments of leptin (ob protein)
CA2381219A1 (en) Monomeric protein of the tgf-beta family
AU2001263215A1 (en) Method for treating cartilage disorders
AU6455896A (en) Novel factor viii:c polypeptide analogs with altered metal-binding properties
AU6207290A (en) Gum composition containing protein macrocolloids
AU6345998A (en) Self-aggregating protein compositions and use as sealants
AU4367196A (en) Novel protein domain which binds tyrosine phosphorylated proteins
AU7352096A (en) Use of thioethers as antioxidant for peptides and proteins and compositions containing the thioethers
AU7017494A (en) Purified mammalian flt3 ligands and agonists and antagonists thereof
BG103872A (en) Glycoconjugates of 20(s)-camptotecin
EP0783521B8 (en) Polypeptide compounds containing d-2-alkyltryptophan capable of promoting the release of growth hormone
AU4263696A (en) Peptides capable of binding to the gap protein sh3 domain, nucleotide sequences coding therefor, and preparation and use thereof
WO1994010207A3 (en) Truncated insulin-like growth factor binding proteins having mitogenic activity
AU5508396A (en) Pcna binding substance
CA2268796A1 (en) Bi-aromatic compounds bound by a heteroethynylene radical and pharmaceutical and cosmetic compositions containing same
CA2201944A1 (en) Analogs of keratinocyte growth factor having enhanced temperature stability
AU3711597A (en) A novel galanin receptor
HUP9904547A3 (en) Benzoxazole derivative with an affinity to binding sites of amino acid receptors and pharmaceutical compositions containing the same

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 131925

Country of ref document: IL

AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM GW HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 1998915236

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2286264

Country of ref document: CA

Ref country code: CA

Ref document number: 2286264

Kind code of ref document: A

Format of ref document f/p: F

Ref country code: JP

Ref document number: 1998 542894

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 69470/98

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 1998915236

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWG Wipo information: grant in national office

Ref document number: 69470/98

Country of ref document: AU

WWG Wipo information: grant in national office

Ref document number: 1998915236

Country of ref document: EP